Clinical Trial Update: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial by Bristol-Myers Squibb evaluating the safety, tolerability, and cerebrospinal fluid biomarker effects of BMS-241027 in subjects with m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-241027

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED